Online Program Home
  My Program

All Times EDT

Abstract Details

Activity Number: 439 - Role of External Evidence in Drug Development: Current Practices and Future Perspectives
Type: Topic Contributed
Date/Time: Thursday, August 6, 2020 : 10:00 AM to 11:50 AM
Sponsor: Biopharmaceutical Section
Abstract #313455
Title: Use of External Evidence for Decision Making in Early Phase Trials
Author(s): Maxine Bennett*
Companies: AstraZeneca
Keywords: early phase trials ; decision making; Bayesian; historical data ; priors ; borrowing

A streamlined drug development process in early phase trials is important to enable efficient delivery of new medicines to patients. Therefore, it is not uncommon for a phase II trial to start recruitment in parallel to an ongoing phase I trial. The data from the phase I trial provides information that can be potentially used to aid decision making in the phase II trial. Within early clinical development at AstraZeneca (AZ), decisions to continue further development of an investigational product are based on a decision-making framework that gives a go, consider or stop recommendation, where these regions are determined from confidence intervals around pre-specified treatment effects. We explore a Bayesian version of the AZ decision criteria incorporating the phase I trial data by utilizing the robust mixture prior. The robust mixture prior will naturally discount the phase I trial data in the final analysis of the phase II trial if there is a difference between the phase I and II data. We explore how incorporating this additional information into the phase II design and analysis may impact development decisions, under different levels of agreement between the phase I and II data.

Authors who are presenting talks have a * after their name.

Back to the full JSM 2020 program